by
Gus Iversen, Editor in Chief | January 23, 2025
BD (Becton, Dickinson and Company) has announced new investments aimed at increasing its U.S. manufacturing capacity for critical medical devices, including syringes, needles, and IV catheters.
The Franklin Lakes, New Jersey-based company said the expansion is part of a broader strategy to strengthen the nation's healthcare supply chain.
In 2024, BD invested over $10 million to upgrade facilities in Connecticut and Nebraska. This funding allowed for the installation of new needle and syringe production lines, one of which is already operational, with additional lines expected to come online in the near future. Once fully operational, these lines are expected to increase BD’s production of safety-engineered injection devices by over 40% and conventional syringes by more than 50%, adding hundreds of millions of units annually to support U.S. healthcare needs.
The company has also hired more than 215 full-time employees to support these manufacturing expansions.
BD plans to further invest $30 million in 2025 to expand IV catheter manufacturing at its plant in Sandy, Utah. This follows a $2 million investment in 2024, which boosted the facility’s output by 40 million units annually.
"Domestic manufacturing is crucial for ensuring a resilient supply of essential healthcare devices," said Eric Borin, president of medication delivery solutions at BD. "By expanding our production capacity, we are not only meeting the critical needs of patients and providers, but we also are reinforcing our commitment to the nation's healthcare infrastructure."
BD operates more than 30 manufacturing and distribution facilities in the U.S., employing over 10,000 people across 17 states and Puerto Rico. Its Connecticut, Nebraska, and Utah facilities, which collectively represent nearly 200 years of manufacturing experience, are key hubs for syringe and catheter production.
The company says these investments highlight its commitment to bolstering the U.S. healthcare supply chain through domestic manufacturing, which it views as essential for meeting future demand and ensuring resilience.
In June 2024, the company
acquired Edwards Lifesciences' Critical Care product group for $4.2 billion in an effort to enhance its portfolio of smart-connected care solutions, and expand its advanced monitoring technology capabilities.
